An old blood-pressure pill for new type 1: what the verapamil trial showed
At EASD 2025 the European Ver-A-T1D trial found the old blood-pressure pill verapamil may protect insulin cells in new type 1, but narrowly missed proof.
At a big European diabetes conference in September 2025, researchers reported that verapamil, a cheap blood-pressure pill that has been around for decades, showed signs of protecting the insulin-making cells that are still left when type 1 is newly diagnosed. The catch is honest and important. The trial, called Ver-A-T1D, narrowly missed the statistical bar for proof. The trend leaned the right way, but it was not strong enough to call settled or to change anyone’s treatment.
- When type 1 is first diagnosed, most people still have some working insulin cells left, and protecting them could make glucose steadier for longer.
- Verapamil is a repurposed drug: it is already licensed for blood pressure and heart rhythm, which is why testing it in type 1 is attractive and low-cost.
- The trial found a trend towards preserving those cells but narrowly missed statistical significance, the bar that tells researchers a result is unlikely to be down to chance.
- UK sites took part, so this is close to home, but a promising trend is not the same as proven or recommended.
- Verapamil is not a type 1 treatment you can start yourself: it is prescription-only and has real effects on the heart and blood pressure.
Protecting what is still there at diagnosis
Type 1 is often pictured as all-or-nothing, but at the point of diagnosis most people still have a fraction of their insulin-making cells alive and working. Over the months afterwards the immune attack usually finishes them off. The idea being tested is simple to say and hard to do: if a medicine could shield those remaining cells, a person might hold on to some of their own insulin for longer, which tends to make glucose steadier and lows less likely.
Verapamil is an old, well-understood blood-pressure drug that earlier laboratory work suggested might protect insulin cells from stress. Because it is already licensed and cheap, it is exactly the kind of drug that, if it worked, could be used widely and quickly rather than costing a fortune. That is the appeal, and it is a good reason to run a proper trial.
Encouraging trend, not a green light
Here is the part to hold onto. Ver-A-T1D did not prove verapamil works. It found a trend in the right direction, towards preserving insulin cells, but the result fell just short of the statistical bar the researchers set to be confident it was real rather than chance. In plain terms, it is a hint worth chasing, not a finding to act on.
That is a normal and useful outcome in research, even if it is frustrating to read. It usually means larger or longer studies are needed to settle the question. For now, verapamil is not part of type 1 care, and nobody should start or change any medication on the strength of a headline. If the idea of protecting insulin cells at diagnosis interests you, that is a conversation for your diabetes team, not a pharmacy purchase.
What a near miss on proof does and does not mean
A near miss on significance sits in an awkward middle. It is more encouraging than a flat negative, because the effect leaned the right way. It is not permission to use the drug, because the study could not rule out that the trend was a fluke. Different trials in different groups can land on either side of that line, which is why one result is rarely the last word.